Pomerantz LLP is investigating Omeros Corporation for possible securities fraud following the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issuing a negative opinion on Omeros's marketing authorization application for narsoplimab, a treatment for TA-TMA. The announcement caused Omeros's stock to fall 19.12% on June 26, 2026. The investigation focuses on whether Omeros and its officers engaged in unlawful business practices related to this event. Investors affected are encouraged to contact Pomerantz LLP for potential class action participation.
Viomi Technology announced it received a Nasdaq notice because its American Depositary Shares (ADS) closed below $1.00 for 30 consecutive business days, failing to meet Nasdaq's minimum bid price rule. The company has 180 days, until January 19, 2027...
On July 22, 2026, Shell plc purchased 75,000 of its own shares for cancellation at an average price of £33.04 per share on the London Stock Exchange. This transaction is part of Shell's previously announced share buy-back program initiated on May 7, ...
The global market for implantable cardiac fluorine-free resins is projected to grow from $1.52 billion in 2025 to $4.26 billion by 2035, at a compound annual growth rate of 10.8%. This growth is driven by rising cardiovascular disease rates, aging po...
Wolters Kluwer repurchased 107,794 of its ordinary shares between July 16 and July 22, 2026, spending €6.6 million at an average price of €61.23 per share. This buyback is part of a larger 2026 program aiming to repurchase up to €500 million worth of...
Valeo has decided to exercise its option for an early redemption (make-whole redemption) of its €750 million bonds bearing a 5.375% coupon due in May 2027. The redemption will take place on August 24, 2026, funded by proceeds from a recently issued €...
